Weinblatt, M. E., Baranauskaite, A., Niebrzydowski, J., Dokoupilova, E., Zielinska, A., Jaworski, J., . . . Tseluyko, V. (2017). Phase III Randomized Study of SB5, an Adalimumab Biosimilar, Versus Reference Adalimumab in Patients With Moderate‐to‐Severe Rheumatoid Arthritis. Arthritis Rheumatol.
Citação norma ChicagoWeinblatt, Michael E., et al. "Phase III Randomized Study of SB5, an Adalimumab Biosimilar, Versus Reference Adalimumab in Patients With Moderate‐to‐Severe Rheumatoid Arthritis." Arthritis Rheumatol 2017.
Citação norma MLAWeinblatt, Michael E., et al. "Phase III Randomized Study of SB5, an Adalimumab Biosimilar, Versus Reference Adalimumab in Patients With Moderate‐to‐Severe Rheumatoid Arthritis." Arthritis Rheumatol 2017.
Nota: a formatação da citação pode não corresponder 100% ao definido pela respectiva norma.